Breaking News Instant updates and real-time market news.

GILD

Gilead

$65.34

1.36 (2.13%)

, GLPG

Galapagos

$188.59

4.36 (2.37%)

11:34
11/10/19
11/10
11:34
11/10/19
11:34

Gilead, Galapagos present filgotinib data that demonstrate durable efficacy

Gilead Sciences (GILD) and Galapagos NV (GLPG) announced detailed results from the companies' clinical research program evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active RA. The data demonstrate durable efficacy and safety results with filgotinib across multiple RA patient populations, from MTX-naive patients to those who have had an inadequate response to two or more biologic disease-modifying antirheumatic drugs. The analyses will be presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting in Atlanta. "These new analyses continue to demonstrate the consistent efficacy and safety profile of filgotinib for a broad range of patients, including those who have already tried other treatments and require other effective and tolerable options," said John Sundy, MD, senior VP, Inflammation and Respiratory Diseases, Gilead Sciences. "With the presentation of these results at ACR, we are one step closer in our journey to deliver upon the promise of filgotinib for patients in need."

GILD

Gilead

$65.34

1.36 (2.13%)

GLPG

Galapagos

$188.59

4.36 (2.37%)

  • 07

    Dec

  • 21

    Feb

GILD Gilead
$65.34

1.36 (2.13%)

10/25/19
MAXM
10/25/19
DOWNGRADE
MAXM
Hold
Gilead downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Gilead to Hold from Buy.
10/25/19
MAXM
10/25/19
DOWNGRADE
Target $66
MAXM
Hold
Gilead downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Gilead to Hold from Buy with a price target of $66, down from $84. The analyst notes that the company's Q3 results were "in line" with expectations, but he remains concerned about its near-term growth prospects. McCarthy points to a lack of potential catalysts as Gilead's HCV revenue continues to erode and its HIV franchise is not enough to generate a "significant" revenue growth.
10/25/19
OPCO
10/25/19
NO CHANGE
Target $80
OPCO
Outperform
Gilead price target lowered to $80 from $85 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Gilead to $80 from $85 and maintained an Outperform rating following the company's Q3 earnings report and investor update. While the quarter was in line with consensus estimates, it missed his expectations by 2% on the top line and bottom line due to one-offs for the HIV/HCV franchise, Singh tells investors in a research note. As new management slot in, Singh says he expects further updates on commercial execution and the pipeline, but HIV continues to be strong, HCV is stabilizing, Yescarta still has "surprising" quarterly variations while the filgotinib filing timelines have firmed up.
10/29/19
RBCM
10/29/19
NO CHANGE
RBCM
Top Pick
Gilead design of Phase 2 study of GS-6207 'intriguing,' says RBC Capital
RBC Capital analyst Brian Abrahams noted that details on Gilead's Phase 2 study for its capsid inhibitor, GS-6207, were posted today on clinicaltrials.gov. He calls the design of the study "intriguing," telling investors that the dose and duration suggest that the drug's profile "may look even better than previously disclosed." The analyst, who sees potential for a transformation of the HIV treatment paradigm away from orals, maintains Gilead shares as a Top Pick.
GLPG Galapagos
$188.59

4.36 (2.37%)

07/31/19
UBSW
07/31/19
UPGRADE
UBSW
Buy
Galapagos upgraded to Buy from Neutral at UBS
09/09/19
MSCO
09/09/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos with an Overweight rating and $200 price target.
09/10/19
MSCO
09/10/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos (GLPG) with an Overweight rating and $200 price target. The analyst believes Galapagos is well positioned for success following the transaction with Gilead (GILD). He believes Gilead offers a "strong partner" to drive the company's "broad" pipeline while building commercial operations in Europe. Filgotinib will drive near-term upside in Galapagos shares while its greater than $5B cash position provides downside protection, Harrison tells investors in a research note.
10/29/19
CANT
10/29/19
NO CHANGE
Target $187
CANT
Overweight
Galapagos outlook unchanged after MOR106 discontinuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle says she still expects a "strong" 2020 from Galapagos following the announcement that clinical development of MOR106 in atopic dermatitis has been stopped for futility. The analyst lowered her price target for the shares to $187 from $188 and reiterates an Overweight rating on the name. She thinks there was "limited investor credit baked in" for the MOR106 program and that Galapagos had relatively limited economics. Many clinical catalysts in 2020 are underappreciated for Galapagos, Merle tells investors in a research note.

TODAY'S FREE FLY STORIES

JCP

J.C. Penney

$1.15

0.055 (5.05%)

, SHLD

Sears

$0.00

(0.00%)

10:19
11/14/19
11/14
10:19
11/14/19
10:19
Earnings
Fly Intel: What to watch in J.C. Penney earnings report »

J.C. Penney (JCP) is…

JCP

J.C. Penney

$1.15

0.055 (5.05%)

SHLD

Sears

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/14/19
11/14
10:17
11/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/14/19
11/14
10:16
11/14/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

$111.77

0.47 (0.42%)

, GLD

SPDR Gold Shares

$138.29

0.31 (0.22%)

10:15
11/14/19
11/14
10:15
11/14/19
10:15
Hot Stocks
Leon Cooperman added Fiserv during Q3 and made stock top holding »

Leon Cooperman disclosed…

FISV

Fiserv

$111.77

0.47 (0.42%)

GLD

SPDR Gold Shares

$138.29

0.31 (0.22%)

GTN

Gray Television

$19.46

0.2 (1.04%)

GCI

Gannett

$9.88

0.04 (0.41%)

STKL

SunOpta

$2.64

0.13 (5.18%)

DT

Dynatrace

$21.28

-0.04 (-0.19%)

LORL

Loral Space & Communications

$37.56

(0.00%)

NRZ

New Residential

$15.80

-0.26 (-1.62%)

PFSI

PennyMac Financial

$31.75

0.1 (0.32%)

TPCO

Tribune Publishing

$9.70

0.1 (1.04%)

NEWM

New Media

$6.65

-0.035 (-0.52%)

WPX

WPX Energy

$10.26

-0.05 (-0.48%)

VICI

VICI Properties

$24.50

0.16 (0.66%)

CCL

Carnival

$44.18

0.12 (0.27%)

TRN

Trinity Industries

$21.21

-0.03 (-0.14%)

TMO

Thermo Fisher

$297.28

-2.62 (-0.87%)

AMCX

AMC Networks

$40.02

0.79 (2.01%)

PARR

Par Pacific

$25.45

0.04 (0.16%)

GOOG

Alphabet

$1,301.47

3.86 (0.30%)

GOOGL

Alphabet Class A

$1,299.66

3.66 (0.28%)

UAL

United Airlines

$92.07

-0.39 (-0.42%)

CIM

Chimera

$20.20

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 02

    Dec

  • 07

    Dec

  • 09

    Dec

PDD

Pinduoduo

$40.92

-0.78 (-1.87%)

10:15
11/14/19
11/14
10:15
11/14/19
10:15
Options
Pinduoduo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

10:15
11/14/19
11/14
10:15
11/14/19
10:15
General news
Breaking General news story  »

Week of 11/8 EIA Natural…

WOR

Worthington

$37.14

-0.11 (-0.30%)

10:14
11/14/19
11/14
10:14
11/14/19
10:14
Initiation
Worthington initiated  »

Worthington initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$19.73

0.09 (0.46%)

10:14
11/14/19
11/14
10:14
11/14/19
10:14
Initiation
Commercial Metals initiated  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
Cleveland-Cliffs initiated  »

Cleveland-Cliffs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
TimkenSteel initiated  »

TimkenSteel initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUE

Nucor

$54.68

-0.01 (-0.02%)

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
Nucor initiated  »

Nucor initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

X

U.S. Steel

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
U.S. Steel initiated  »

U.S. Steel initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RS

Reliance Steel

$113.82

0.16 (0.14%)

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
Reliance Steel initiated  »

Reliance Steel initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$2.61

-0.03 (-1.14%)

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
AK Steel initiated  »

AK Steel initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$31.54

0.19 (0.61%)

10:13
11/14/19
11/14
10:13
11/14/19
10:13
Initiation
Steel Dynamics initiated  »

Steel Dynamics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,765.00

11.16 (0.64%)

, GOOG

Alphabet

$1,299.36

1.75 (0.13%)

10:09
11/14/19
11/14
10:09
11/14/19
10:09
Conference/Events
House Committee on Small Business to hold a hearing »

The Committee holds a…

AMZN

Amazon.com

$1,765.00

11.16 (0.64%)

GOOG

Alphabet

$1,299.36

1.75 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

EPAM

Epam Systems

$202.00

1.26 (0.63%)

, GLYC

GlycoMimetics

$6.38

0.11 (1.75%)

10:07
11/14/19
11/14
10:07
11/14/19
10:07
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

EPAM

Epam Systems

$202.00

1.26 (0.63%)

GLYC

GlycoMimetics

$6.38

0.11 (1.75%)

JHX

James Hardie

$19.80

(0.00%)

VIR

Vir Biotechnology

$13.25

0.19 (1.45%)

SACH

Sachem Capital

$4.27

0.01 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AAPL

Apple

$264.60

0.08 (0.03%)

, KHC

Kraft Heinz

$32.10

-0.79 (-2.40%)

10:07
11/14/19
11/14
10:07
11/14/19
10:07
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

AAPL

Apple

$264.60

0.08 (0.03%)

KHC

Kraft Heinz

$32.10

-0.79 (-2.40%)

VZ

Verizon

$59.22

-0.19 (-0.32%)

T

AT&T

$39.03

-0.125 (-0.32%)

TMUS

T-Mobile

$77.54

-0.48 (-0.62%)

MYO

Myomo

$0.54

-0.0029 (-0.54%)

ALB

Albemarle

$64.10

-1.15 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 29

    Jan

  • 30

    Jan

UBER

Uber

$26.61

-0.09 (-0.34%)

, SWK

Stanley Black & Decker

$157.09

1.715 (1.10%)

10:07
11/14/19
11/14
10:07
11/14/19
10:07
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

UBER

Uber

$26.61

-0.09 (-0.34%)

SWK

Stanley Black & Decker

$157.09

1.715 (1.10%)

FVRR

Fiverr

$23.29

0.74 (3.28%)

MTOR

Meritor

$24.83

1.05 (4.42%)

ALSN

Allison Transmission

$45.33

1.04 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

  • 12

    Dec

WHLR

Wheeler REIT

$1.92

(0.00%)

10:05
11/14/19
11/14
10:05
11/14/19
10:05
Hot Stocks
Stilwell Group says Wheeler REIT CEO is 'being misleading' about meeting »

The Stilwell Group, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$42.21

-1.08 (-2.49%)

10:05
11/14/19
11/14
10:05
11/14/19
10:05
Options
Lyft call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 09

    Dec

10:05
11/14/19
11/14
10:05
11/14/19
10:05
General news
Fed Chair is back on Capitol Hill, before the House Budget Committee »

Fed Chair is back on…

10:04
11/14/19
11/14
10:04
11/14/19
10:04
Hot Stocks
Breaking Hot Stocks news story  »

TKK Symphony Acquisition…

UBER

Uber

$26.52

-0.18 (-0.67%)

, LYFT

Lyft

$42.16

-1.13 (-2.61%)

10:03
11/14/19
11/14
10:03
11/14/19
10:03
Periodicals
Uber reportedly owes New Jersey $650M in unpaid taxes »

New Jersey's…

UBER

Uber

$26.52

-0.18 (-0.67%)

LYFT

Lyft

$42.16

-1.13 (-2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

I

Intelsat

$12.64

-1.77 (-12.28%)

10:00
11/14/19
11/14
10:00
11/14/19
10:00
Hot Stocks
Intelsat falls -12.2% »

Intelsat is down -12.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.